Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Remdesivir-Associated Significant Bradycardia: A Report of Three Cases Publisher



Shirvani M1 ; Sayad B1 ; Shojaei L2 ; Amini A3 ; Shahbazi F2
Authors

Source: Journal of Tehran University Heart Center Published:2021


Abstract

Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients’ heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects. © 2021 Tehran University of Medical Sciences.
Related Docs
View other Related Docs
1. Effect of Covid-19 Medications on Corrected Qt Interval and Induction of Torsade De Pointes: Results of a Multicenter National Survey, International Journal of Clinical Practice (2021)
2. Cardiovascular Implications of the Covid-19: Management of Complications and Drug Safety Concerns, Journal of Research in Medical Sciences (2022)
3. Investigation of Effective Drugs in the Treatment of Patients With Covid-19, Journal of Iranian Medical Council (2023)
Experts (# of related papers)
View all Related Experts
Azita Hajhossein Talasaz (4)
Babak Geraiely (2)
Other Related Docs
4. Remdesivir Administration in Covid-19 Patients With Renal Impairment: A Systematic Review, American Journal of Therapeutics (2022)
5. Remdesivir: A Beacon of Hope From Ebola Virus Disease to Covid-19, Reviews in Medical Virology (2020)
6. Safety and Efficacy of Remdesivir for the Treatment of Covid-19: A Rapid Review of Available Evidence, Health Technology Assessment in Action (2020)
7. The Efficacy of Remdesivir in Coronavirus Disease 2019 (Covid-19): A Systematic Review, Iranian Journal of Microbiology (2020)
8. Evaluation of Clinical Outcomes in Covid-19 Patients Receiving Remdesivir in Outpatient Setting, Iranian Journal of Pharmaceutical Sciences (2024)
9. A Systematic Review of Ecg Findings in Patients With Covid-19, Indian Heart Journal (2020)
10. The Drug Effectiveness and Side Effects of Remdesivir in Neonatal Covid-19: A Case Series Study, Archives of Pediatric Infectious Diseases (2024)
11. Effects of Remdesivir on In-Hospital and Late Outcomes of Patients With Confirmed or Clinically Suspected Covid-19: A Propensity Score-Matched Study, Acta Medica Iranica (2022)
12. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (Covid-19), Journal of Cardiovascular Pharmacology (2020)
13. Therapeutic Strategies for Covid-19 Patients: An Update, Infectious Disorders - Drug Targets (2022)
14. Covid-19 and Cardiovascular Diseases, Advances in Experimental Medicine and Biology (2021)
15. A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection, Cor et Vasa (2021)
16. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of Covid-19, Cardiovascular and Hematological Disorders - Drug Targets (2021)
17. Cardiovascular Complications of Covid-19: Pharmacotherapy Perspective, Cardiovascular Drugs and Therapy (2021)
18. Remdesivir Versus Sotrovimab in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis, Health Science Reports (2025)
19. Clinical Outcomes and Considerations in Outpatient With Covid-19 Receiving Remdesivir Therapy, Health Science Reports (2024)
20. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)